- Advertise
- Contact Editorial
- Editorial Submission Guidelines
- Contact MJH Life Sciences
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Pharmaceutical Executive-08-01-2022
The Silver Lining Of Innovation in Genetic Medicine
August 10, 2022
Back Page
42
8
Failed efforts do not overshadow field’s progress, resolve.
Navigating the Financial Meltdown for Biopharma
August 10, 2022
Finance
42
8
A review of pharma and biotech equity market, IPO, and M&A trends and outputs through the first half of 2022—and implications for the future as disruptions continue to have an impact.
Pharma’s Training Transformation: COVID Forces Compliance Revamp, Re-education
August 10, 2022
Features
42
8
How one company in particular has adjusted its internal and customer-facing strategies in compliance training amid today’s heightened business-risk climate.
A Cross-Functional Formula: Operationalizing the Broader Role of Access
August 10, 2022
Features
42
8
The BCG Market Access Roundtable outlines the new and advanced access competencies required to enable functional operationalization and delivery of this critical role in biopharma—today a key strategic partner in achieving overall business goals.
The Potential of Proteomics
August 10, 2022
Features
42
8
Major stakeholders—including policymakers, public-private interests, and academia—are increasingly embracing the potential of proteomics technology in reshaping diagnostics and patient care.
Getting ‘Personal’ With Vaccine Development
August 10, 2022
Features
42
8
Innovative and continuous remote patient monitoring, along with AI-based predictive analytics, are advancing progress toward replacing the one-size-fits-all, population-driven vaccination model.
The Price of Innovation: ‘Paying for a Cure’ Remains Costly Proposition
August 10, 2022
Features
42
8
Curative-type therapies offer great hope in further transforming treatments for cancer and other diseases, but addressing the economics of these products—and ultimately the cost-benefit equation—is daunting. What is being done to smooth the path for pricing and reimbursement?
Milestones and Momentum: Assessing Advancements in Personalized Medicine
August 10, 2022
Features
42
8
The road to precision medicine as a fixture in healthcare delivery is still a journey, but recent advances and new understandings in gene profiling, biomarker development, and AI and data analytics are steadily bringing these therapies closer to the individual patient every day.
A World of Opportunity
August 10, 2022
Executive Profile
42
8
Marie-France Tschudin, president, innovative medicines international, and chief commercial officer at Novartis, taps into life lessons to help bring therapies to people in novel ways.
Has Biotech Bottomed Out—and is Recent Recovery Sustainable?
August 10, 2022
Finance
42
8
A look at the driving factors behind renewed optimism.
AI Opens Door To Improving Patient Experience
August 10, 2022
Technology
42
8
The technology is not just about digital enablement anymore.
Meeting the Moment: ESG Strategy and the Business of Resilience
August 10, 2022
ESG
42
8
How principles of both can help companies navigate future storms.
Optimism Abounds On New EU Blood And Tissue Rules
August 10, 2022
Europe Report
42
8
Proposed SoHO reform elicits wide support, but risks acknowledged.
Voyage to Mainstream
August 10, 2022
From the Editor
42
8
Personalized medicine here to stay after massive uptick in 2021 approvals.
Pharmaceutical Executive, August 2022 Issue (PDF)
August 10, 2022
Issue PDF
42
8
Click the title above for a link to open the Pharmaceutical Executive August 2022 issue in an interactive PDF format.
FDA Joins Effort to Curb Drug Patent Abuses
July 11, 2022
Washington Report
42
8
Agency partners with patent office in addressing anticompetitive practices.